EVA Pharma Granted License to Manufacture and Distribute “Remdesivir” in 127 countries
Egypt, June 14, 2020
Having reached a landmark agreement with Gilead Sciences Inc., EVA Pharma is proud to announce that it is now a licensed manufacturer for the antiviral treatment Remdesivir in 127 countries. This game-changing development establishes EVA Pharma’s position as a global leader in the battle against COVID-19. Accordingly, it will work at ‘full capacity’ while leveraging its far-reaching network to meet the onerous challenge of alacritous providing Remdesivir to all COVID-19 patients in 127 countries.
“This voluntary license agreement comes at a critical time as the virus has started to spread in developing countries whose health-care systems are already severely strained. It is our duty to rise to the occasion and support our fellow man as humanity collectively strives to put an end to this pandemic. EVA Pharma is therefore working tirelessly and assiduously to ensure the availability of life-saving drugs to COVID-19 patients”
said EVA Pharma CEO, Riad Armanious.
EVA group and Gilead have a history of highly successful partnerships, having fruitfully collaborated in the past to provide accessible, affordable, and high-quality treatments of otherwise lethal infectious diseases such as HIV and hepatitis C to millions of patients in Africa.
“We are thrilled to have been chosen to work side-by-side with Gilead
sciences once more. We strongly believe that our partnership with
Gilead will help us realize our vision of empowering the fight for health
and well-being as a human right”
Remdesivir is an investigational new drug developed by Gilead Sciences. The treatment has recently been granted an emergency use authorization (EUA) to treat hospitalized COVID-19 patients in the U.S and the UK.
Besides, it is recommended for compassionate use in Europe and recently received regulatory approval in Japan. Two global clinical trials conducted to date have demonstrated positive results, reducing the recovery time for patients with COVID-19, although the full efficacy and safety of the treatment are still under investigation. The voluntary license agreement provides EVA Pharma with Gilead’s technology, manufacturing process descriptions, specifications, and methods to boost the production timeline of Remdesivir.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at gilead.com
About EVA Pharma
EVA Pharma is a leading international pharmaceutical company based in Cairo, Egypt, and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 42 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, EVA Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards. To learn more about EVA Pharma, please visit evapharma.com